Astellas gains an option on Audax’s IL-12 antibody-cytokine fusion DAX-044, while EVERSANA acquires London-based health economics firm Estima Scientific.
|Articles|June 9, 2022
- Pharmaceutical Executive-06-01-2022
- Volume 42
- Issue 6
Pharmaceutical Executive, June 2022 Issue (PDF)
Advertisement
Articles in this issue
over 4 years ago
2022 Pharm Exec Top 50 Companiesover 4 years ago
The Emergence of the Chief Value Officer in Healthcareover 4 years ago
Sustainability Sea Change: The Top 5 ESG Challenges for Pharmaover 4 years ago
Is the C-Suite Getting Inflated?over 4 years ago
Clinical Composerover 4 years ago
Are We Closer Than Ever to a Biotech Bottom?over 4 years ago
DE&I in Pharma: Good for People—and Businessover 4 years ago
Early Input Necessary in Creating Smooth C-Suite Transitionsover 4 years ago
A Storm in a Brussels Teacup Could Threaten Drug-Pricing Watersover 4 years ago
Fresh Talent Awaits, But Must Be Tech-SavvyAdvertisement
Related to this article
Shionogi’s Dr. Draica on why preventative antivirals matter — and how its HIV and flu prevention heritage shaped XOCOVA’s post-exposure focus.
The infrastructure decisions companies make today could determine how quickly they capitalize on new computational capabilities
Brox.AI’s Hamish Brocklebank on three levels of digital clone use cases — from HCP content testing and GLP-1 price sensitivity modeling to simulating physician adoption after FDA approval.
The top barrier to AI adoption among pharma commercial leaders is compliance uncertainty, and the fix may be governance that evaluates one use case at a time.
Teva acquires BioXcel’s BXCL501, under FDA review for at-home agitation use; Rumi Therapeutics gains an option on Enthorin’s Fragile X PDE2 inhibitor.
Brox.AI’s Hamish Brocklebank on the three approaches to digital twins in pharma — and why only one-to-one clones of real individuals deliver true accuracy.
Shionogi’s Dr. Draica on how XOCOVA blocks viral replication between exposure and symptoms — and why it works even with prior immunity.
Advertisement
Advertisement
Trending on PharmExec
1
The Next Biopharma Revolution: Quantum Computing
2
How Medications like XOCOVA Prevent Illness After Exposure to COVID-19
3
Roundup: Teva Acquires BXCL501 for $57.5 Million Upfront, Rumi Therapeutics Enters Option Agreement for Fragile X PDE2 Inhibitor From Enthorin
4
Roundup: Astellas Licenses IL-12 Fusion Protein From Audax in Deal Worth Up to $1.34 Billion, EVERSANA Acquires Health Economics Firm Estima Scientific
5